Drugs / TEG002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04688853 | May 2021 → Jul 2023 | plasma cell myeloma | Gadeta B.V. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TEG002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04688853 ↗ |
| Modality | Cell therapy | “autologous T cells transduced with a specific γδTCR” NCT04688853 ↗ |